On November 9 2023, APYX MEDICAL ($NASDAQ:APYX) revealed its financial results for the third quarter of FY2023, which had concluded on September 30 2023. The company reported total revenue of USD 12.0 million, representing a year-on-year rise of 31.5%. Net income for the period was -4.6 million, a decrease from -5.8 million in the same quarter of the previous fiscal year.
On Thursday, APYX MEDICAL announced record-breaking earnings results for its fiscal year ending 2023 Q3. This was an unexpected turn of events due to the pandemic and the challenges that APYX MEDICAL had faced during the same year. Despite this, the company was still able to report record-breaking earnings.
However, despite the good news of the record-breaking results, APYX MEDICAL stock opened at $1.9 and closed at $1.6, plunging by 20.3% from previous closing price of 2.1. This was likely due to investors not trusting the company’s ability to sustain the earnings reported in the results. Nevertheless, it is important to note that the company managed to come through despite the difficult times and report good results. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Apyx Medical. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Apyx Medical. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Apyx Medical. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Apyx Medical are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Apyx Medical Intrinsic Value Calculation
At GoodWhale, we’ve conducted an extensive analysis of APYX MEDICAL‘s fundamentals. After careful consideration, we’ve determined that the intrinsic value of APYX MEDICAL’s share is around $8.4. This figure was calculated using our proprietary Valuation Line. Currently, APYX MEDICAL’s stock is being traded at $1.6, indicating that it is undervalued by 80.9%. Therefore, investors may find this a great opportunity to purchase the stock at a discount. More…
Star Chart Analysis
The medical device industry is highly competitive, with Apyx Medical Corp competing against Therma Bright Inc, NeuroOne Medical Technologies Corp, and Brain Scientific Inc. All four companies are vying for a share of the market, with each company offering a unique product or service.
– Therma Bright Inc ($TSXV:THRM)
Therma Bright Inc is a medical device company that develops, manufactures, and markets LED-based therapies. Its products are used for the treatment of acne, psoriasis, and other skin conditions. The company has a market cap of 31.14M as of 2022 and a return on equity of -263.61%.
– NeuroOne Medical Technologies Corp ($NASDAQ:NMTC)
NeuroOne Medical Technologies Corp is a medical device company that develops and commercializes electrode technologies for the treatment of neurological disorders. The company has a market cap of 15.89M and a ROE of -59.33%. The company’s electrode technologies are based on a thin-film platform that is designed to provide superior performance and patient outcomes. The company’s products are used in a variety of neurosurgical procedures, including deep brain stimulation, epilepsy surgery, and neurostimulation.
– Brain Scientific Inc ($OTCPK:BRSF)
NeuroScientific Inc is a biotechnology company that focuses on the development and commercialization of drugs for the treatment of neurological disorders. The company has a market cap of 12.24M as of 2022 and a return on equity of 632.23%. NeuroScientific’s products are designed to target specific areas of the brain, which the company believes will lead to more effective treatments for neurological disorders. The company’s products are in various stages of development, and it has partnered with several major pharmaceutical companies to commercialize its products.
APYX MEDICAL reported its earnings for the third quarter of FY2023 on November 9th, showing a 31.5% year-over-year increase in revenue to USD 12.0 million. Net income, however, decreased from -5.8 million to -4.6 million. The stock market reacted negatively to these results, with the share price dropping accordingly.
This suggests that investors have some concerns over APYX MEDICAL’s performance and long-term prospects. It is important for investors to carefully examine the company’s financials and understand the drivers of its performance before making any investment decisions.